How It's doing
Immunotherapy treatment Clevegen is in a phase I/II trial (MATINS) for metastatic cutaneous melanoma as well as hepatobiliary/hepatocellular, pancreatic, ovarian and colorectal cancers.
Tumour cells are adept at creating a shield around themselves to evade detection by the immune system, therefore staving off destruction.
Clevegen has been designed to recognise cancer and break the tumour's protective shell.
The treatment is an anti-Clever-1 antibody which causes changes in the immune environment of solid tumours by switching Clever-1 positive immune suppressive macrophages to immune active macrophages.
Ultimately, if it is successful, this new breed of treatment will be used in combination with PD-1 inhibitors to tackle the killer disease.
In April, Faron was given the green light to broaden the scope of its phase I/II cancer trial after a review of the interim data.
The MATINS study of the immunotherapy Clevegen will now take in seven further strains of the disease besides the two already assessed - colorectal and ovarian
Traumakine has been rejuvenated following the disappointment over its phase III trial result.
As a treatment for lung inflammation condition ARDS its missed its target with no benefit against the placebo.
However, since then Faron has identified that it was steroids used alongside the drug that led to the unexpected result.
Traumakine is an interferon-beta that helps to stop lung inflammation and has come to the fore as a way potentially to help severe coronavirus sufferers.
The latest development has seen Traumakine admitted to a large-scale global programme (REMAP-CAP) that will assess its potential in treating severe pneumonia, including patients with coronavirus (COVID-19).
Faron said its interferon beta-1 formulation will be delivered intravenously, which the company reckons offers the best “delivery route” for critically ill patients.
It will also be compared in the study with other treatments, including hydrocortisone medications.
These steroid-based interventions, used in patients in respiratory distress, were seen as the potential root cause of a failed Faron phase III study of Traumakine.
What the boss says: Markku Jalkanen, CEO
“The design of the REMAP-CAP trial will enable study subjects to be initiated onto investigational IV IFN beta-1a treatment relatively rapidly, on submission to intensive care, and before the development of ARDS [acute respiratory distress],” said CEO Jalkanen.
“Many of these patients have a severe viral infection and so are an optimal target cohort for the Traumakine-project and the investigation of its potential.”
• Faron finds a partner from the many said to be watching the MATINS trial data
• Shares have soared as MATINS trial data started to be released and potential of Traumakine
• Traumakine reboots as a treatment to ease ARDS sufferers following coronavirus infection